kabutan

GNI Group Ltd.(2160) Summary

2160
TSE Growth
GNI Group Ltd.
3,165
JPY
+55
(+1.77%)
Apr 28, 3:30 pm JST
19.88
USD
Apr 28, 2:30 am EDT
Result
PTS
outside of trading hours
3,118
Apr 28, 11:58 pm JST
Summary Chart Historical News Financial Result
PER
PBR
3.51
Yield
ー%
Margin Trading Ratio
41.51
Stock Price
Apr 28, 2026
Opening Apr 28, 9:00 am
3,125 JPY 19.60 USD
Previous Close Apr 27
3,110 JPY 19.51 USD
High Apr 28, 2:54 pm
3,170 JPY 19.91 USD
Low Apr 28, 9:02 am
3,100 JPY 19.45 USD
Volume
389,100
Trading Value
1.22B JPY 7.68M USD
VWAP
3142.88 JPY 19.74 USD
Minimum Trading Value
316,500 JPY 1,988 USD
Market Cap
0.18T JPY 1.11B USD
Number of Trades
810
Liquidity & Number of Trades
As of Apr 28, 2026
Liquidity
High
1-Year Average
3,407
1-Year High May 27, 2025
36,454
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 602,200 7,220,700 11.99
Apr 17, 2026 623,600 7,098,400 11.38
Apr 10, 2026 615,600 7,142,400 11.60
Apr 3, 2026 596,300 7,120,500 11.94
Mar 27, 2026 618,700 7,690,000 12.43
Company Profile
GNI Group Ltd. is a biotech venture company focused on drug discovery. It has research and development centers in the United States and China. The company's main product is a drug for idiopathic pulmonary fibrosis. They are also involved in genetic analysis.
Sector
Pharmaceuticals
GNI Group Ltd. operates in both the pharmaceutical and medical device sectors. In its pharmaceutical business, the company sells F351 (Etuary), a treatment for fibrosis, in the Chinese market. They also conduct research, development, manufacturing, and sales of drug compounds targeting lung diseases (interstitial lung diseases), liver diseases, and kidney diseases (chronic kidney disease). The medical device business is based in the United States and focuses on the development, manufacturing, and sales of biomaterials. The group consists of the parent company, 18 consolidated subsidiaries, and 2 affiliated companies. They also provide services such as reagents, designated manufacturing and marketing of medical devices, and domestic clinical trial management.